Avidity Biosciences Announces FDA Clearance of IND Application for AOC 1044
PPMD is excited to share that Avidity Biosciences has announced that they have received clearance from the FDA on their Investigational New Drug (IND) application for AOC 1044, an exon skipping therapy targeting those amenable to exon…Learn More
